CRISPR's Path to the Clinic

Since the establishment of CRISPR as a ubiquitous new technology for genome editing, it has been touted as a transformational tool in medicine. Numerous biotech companies are leading the charge to turn the promise of CRISPR at the bench into a paradigm-shifting therapy at the bedside. Last year, researchers published results on the first successful CRISPR-based treatment for major genetic disorders – sickle-cell disease and beta-thalassemia – with many others poised to follow.

The CRISPR Journal is pleased to announce a new special issue – “CRISPR's Path to the Clinic” – to be published in 2022. We invite researchers and clinicians to submit papers on original research on any aspect of CRISPR research that has implications for gene therapy and medical treatments. We will also consider relevant guest commentaries and review articles.

Specific topics may include (but are not confined to):

• Preclinical and translational research
• New tools for gene therapy
• Advances in base and prime editing
• Viral and non-viral delivery systems
• Safety and immunological issues
• Animal models
• Ethical considerations

Manuscripts will receive prompt peer review and accepted articles will be published online (epub) ahead of print. Please refer to our Instructions for Authors before submitting your manuscript for consideration.

Informal pre-submission inquiries may be sent to the CRISPR Journal editorial office. This special issue will be published in 2022; the deadline for submissions is October 15, 2021.

Advantages of publishing in The CRISPR Journal include:

• Rapid, high-quality peer review and editorial oversight
• Fast and user-friendly electronic submission
• Maximum exposure: accessible in 170 countries worldwide
• High visibility: International press and social media outreach
• Open Access options available
• Indexed in Medline
• Impact Factor: 6.071
• Translation, language-editing, and research promotion services available